ORLANDO, Florida — A post hoc analysis of phase 3 studies in patients with relapsing-remitting multiple sclerosis (RRMS) clearly showed that those taking the oral agent BG-12 (dimethyl fumarate; ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback